Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
But breaking Pfizer and Merck’s duopoly will not be easy.
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
First-quarter venture investments barely register the pandemic - huge cash reserves should protect funding for biotech start-ups this year.
Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.